We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pfizer has nominated the fourth and fifth targets of the collaboration, designed to apply Wave’s stereochemistry platform across antisense and single-stranded RNA interference (RNAi) modalities